Medicus Pharma's SkinJect Shows 73% Clinical Clearance in Phase 2 Trial
Event summary
- Medicus Pharma's Phase 2 trial (SKNJCT-003) for SkinJect showed 73% clinical clearance and 40% histological clearance in the 200μg cohort at Day 57.
- The study enrolled 90 patients with nodular basal cell carcinoma (BCC) across three cohorts: placebo, 100μg D-MNA, and 200μg D-MNA.
- Medicus plans to seek an end-of-Phase 2 meeting with the FDA in the first half of 2026.
- The company aims to accelerate partnering discussions based on the topline results.
The big picture
Medicus Pharma's positive Phase 2 results for SkinJect position the company to advance its non-invasive treatment for basal cell carcinoma. The data strengthens its partnering strategy, as Medicus aims to license or strategically partner with established pharmaceutical companies for late-stage development and commercialization. The biotech sector continues to focus on innovative delivery mechanisms for cancer treatments, and Medicus's microneedle technology could disrupt traditional treatment methods if successfully commercialized.
What we're watching
- Regulatory Pathway
- Whether the FDA will grant an end-of-Phase 2 meeting and the timeline for potential regulatory approval.
- Partnering Strategy
- The pace at which Medicus can secure strategic partnerships based on the Phase 2 data.
- Clinical Development
- How the continued biological activity observed at Day 57 will impact the design of future clinical trials.
Related topics